Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf%$# 10-20 , " 40 .
" & 2-4 1 , " %$# 4-8 , " 8 .
" , #"*
< &
@ " "
# II ( $" & % % ?;1- 3 B?_ " ? " ). 7 " 300-600 / ?@.
" , II
? + & B?_ ( &)
@ "
? + !@
? + !+
? + "
JD
" , II
< &
@ " "
#
" ,
? + "
? + !@
( $" & % %0,2-0,4 / )
7 8 ,
?'- II-III
? + % !+
# |
|
|
|
@ " V "- % (B6, |
|
& , &) |
& 75 |
|
/ 3% >10% 10 '. ' " ,
$ |
50 ? " |
||||
% |
- / !@ / |
||||
|
"$. |
||||
; |
|
|
|
( , ). |
|
|
B |
|
$ &$ B6, |
||
" ," % ($" . ? , "B<! & ) % % % % & 3 ( , ).
? + B<!, , !@ #4,5 &/ G! J + 2,5 &/ .
& $ $, &"& « » " ?@
?_,
& . - & ( ), ?_.?_II
" & :
1.* , 12,5-25
2.**B , 2,5
3.*6 , 50-200 \
4.**7 , 2,5 , 10 ; 1,25 /1
5.*J , 5-40
6.* 2-8
7.7 , 300-600 \
8.**? , 5 , 10
9.*' , 240-480
10.*@ , 1-16
11.6 , 02-0,4 \
" & & :
1.*? , 75 \
2.? , 10-80
3.! , 5-80
4.*J , 10-40
,- ! ( !$$ ):
?@
" "
" "
% , . @ II $
: % " &, " "& , " "?@ (140/90 . . . % ).
/ , & :
1.Essential hypertension. Guedelines for clinical care. University of Michigan Health system. 2002
2.VHA/DOD Clinical practice guideline for diagnosis and management of hypertension in the primary care setting. 1999.
3.Prodigy guidance. Hypertension. 2003.
4.Management of hypertension in adults in primary care. National institute for clinical excellence. 2004
5.Guidelines and protocols. Detection and diagnosis of hypertension. British Columbia medical association. 2003
6.Michigan quality improvement consortium. Medical management of adults with essential hypertension. 2003
7. ? & . ! & V $"$ & % & , .2003.
8.> # & > #2003. "$ & . J.hypertension 2003;21:1011-53
9." $ " " . B.+.@ , M.J.K " .6.2004.
10.The 2003 Canadian Recommendations for the management of hypertension diagnosis.
11.The Seventh Report of the Joint national Committee on prevention, Detection, Evaluation
and treatment of high blood pressure. 2003.
12.?.+. @ , 7.
13.D.@., M.'. ? & 2000: $"
. @ , |
. " . |
|
14. |
_& |
&$ ( |
). ' 6. 6 , 2005. |
|
|
* – |
, # (% % ) |
|
** |
- " & |
, " |
$ &
;
: 10-106
"$ &: "
: 6!
& !: , &, & , "$, , " % .
' & & : %(:
>01 < # % , " &$ >02 ! " "
>03.9 " >04 @ "
>00 ! % " ) : ; – " ,# %
$ :
$ % - -# % : " " "
" ( , )% :
" ( &;; )
( , )
% ( , " " &, " ,
, ). |
|
|
|
|
|||
|
$# |
& |
" |
|
(90% |
) |
|
|
% |
# % , |
& |
|
" |
||
. 3 : |
|
|
|
|
|||
- |
&- # % : |
||||||
) " ; |
|
|
|
|
|||
) # % ; |
|
|
|
||||
) I 131; |
|
|
|
|
|
||
) |
# , |
; |
|||||
) & ; ) # % ;
) " # % .
-:
) % ) %
) " ( ,.).
' " " $ % & ,$ :
- , $# ;; / ;
-;; / ;
/ & % " / % ;; / ; . " &:
)
4.# – , 1 3 , & – 2 .
5.7 – , & –1 2-4 ( % % ),%$# 1 6 , "
" – " # . 6. & 3
" & & :
1.H)B # %
2.# %
4.; 6 ; ( & )
5. & , –
6.&
7.&
+ :
. + " & %$# $ & " , ,
"- . |
|
||
+ " & |
" 50 , |
||
" 12,5 |
– 25 |
% 1-2 & , |
;; , |
- 7 . ! |
%$# 1,6 / , & |
||
% & |
. H % & |
|
|
" & " 12,5 , " ( % 1- 3 ) 7 ;; 12,5-25 . H& . $ 1&, 30 .
& #$ " & $ ;; , % & 0,5 2,0 6>/ , % 2,0 4,0 6>/ .
" & :
1.*J 25 , 50 ,75 , 100 , 125 , 150 , .
" & & :
2." " – . «! " " &»
3.& – " , " ( )
4.– " , "
5."
,- ! :
1. ! , 3 "
2.+ " %
/ , & :
1." $# " , &2- , 2002 .
2.% ; 13, 86 (230) 2005 .
3.Clinical Evidence Endocrine and Metabolic Disorders Primary hypothyroidism Treating overt hypothyroidism Levothyroxine www.clinicalevidence.com
4.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. www.guideline.gov
5. ! “) % " |
” 88 7 . |
. +.J . . – 6., , 1999 |
. – 1128 ., . |
* – , # (% % )
: 09-102 |
|
' |
|
|
|
|
|
|
|
"$ &: " , |
& & - |
|
||
: 6! |
|
|
|
|
& ! : % |
; & & |
" |
||
" |
|
|
||
' & & : |
|
|
|
|
4 ( % , |
% ); |
|||
12 & ( " , ). |
|
|||
(: |
|
|
|
|
'35 @ |
|
|
|
|
'36 @ |
|
|
||
) : ' - 3 |
% % |
, |
||
. |
|
|
||
$ : ( ? " , |
+.@. K ) |
|
||
. : |
; |
( & ), |
3 , |
|
" .
.@ : 3 , , , ; .
. % , " .
V. % % ( ,, ) - .
* : % ( ); % & ( &) % 3 ; & % ; % ; "( , & % & ); " # " ; -# "
|
% |
|
% ; |
3 |
; |
|||
" |
; |
|
; |
|
|
|
||
|
( |
.: |
, |
& , |
$); |
|||
& " % . |
|
|||||||
|
: |
|
|
|
|
|
||
1.! 3 " .
2.: & -% " , % , $" " " , ; % & < & 5% - .; % " 3 .
3.; ( & ): " & ,& ; & - " ( & ) " (" & ); " % .
4.7 : " -% %V " , " % , % " ;
" ; " |
" " % |
||
" |
" ; |
& , , 3 , " , |
|
" ; % # . |
|||
5. |
6 |
: % |
, |
; , % , ; % % & % & , & ,, ; , $# 3 ;$ 3 , # ; V- , %% , &.
6.( ): " - , #
- % |
, # ; |
" |
- -, , #$ $ |
& , " " $ ( ); " - % " , % % , % "" .
7.6 % : - $" , " , & " ," ; " " .
8.6 " : " , " (2-3 ); # " - ;(3-4 % ); « & » . ; &-& ( " & , & ): " # $ -
&$; , 3 , , " ; & , ; , $; " " . @" & $
9.% : & ,$ $ 3 , 3 " $; % &. : " &,; " , , .
10.J % .
" & :
1. 6 ;
2. H)B $ ( );
3.# ;
4.# " ;
5.<
" & & : |
|
|
|
||||||
1. |
< " |
|
(?J;, ?!;, # |
, |
|
) |
|
||
|
|
|
|
|
|
|
|
|
|
+ |
: |
|
|
|
|
|
|
|
|
! ( , , & ) |
$: |
|
|||||||
" |
% % ; |
% |
|||||||
; " |
; |
, $" |
|||||||
" , |
;-" |
; |
|||||||
&$ $ $. |
|
|
|
|
|
|
|||
1. |
B ( & 10 \ , .100 ): 100 / .- 2 . 200 |
||||||||
/ .- 7 . |
% |
: 200 % 12 "- 7 |
|||||||
, 3- & |
(2 |
&- ). |
% |
|
|||||
: 200 % 12 "- 7 , 3- & |
(3 &- |
). |
|
||||||
2.; ( .250 ): 250 / .-1 , - 3 . @ ( 3- ) "$ : 20 - 62,5 ; 20 40 -125 .
3.+ % : (1% , 3 & ), 5% - &,(5% )- " ,(1% , 1% ), (2% ), 5% .
' ! 8 & $ 8
: 18 – 147
"$ &: "
: 6!
& ! :
1.;
2." /+!;
3." ;
4.;
5.-3 .
' & & : 5
(: ?-09 @ 3 % & % ) : ' – " % 3 " 24
" V , $# 200 / .
>$ ! – " % " & : , , , , ( ) % , " % . % & & 14 .
$ :
* : Salmonella, Shigella, Esherichia coli, Vibrio cholerae, Yersinia, Campilobacter, Rotavirus and etc., Lamblia intestinalis.
:
1." :
-" ;
-;
-, ;
-% ;
-" ;
-%
2. " :
-# (" , % & , , % & % );
-& % ( , % , &, , % & % % , % );
- " & ;
-& ;
-& % , & " ($" % " : , " &, & )
" & :
1.#
2.# "
3.( % , 3 )
4.< .
5.- .
" & & :
1. + : & 2 % "
24 " . ' $# 200 % " .
: